Epigenic Therapeutics
- Biotech or pharma, therapeutic R&D
Epigenic Therapeutics developed two groundbreaking technologies - epigenetic modulation (next-wave gene therapy), and in-vivo LNP delivery. We seek partnership on our pipelines and platform technologies.
Pipeline focuses on EPI-001 (PCSK9, next-generation product) with a only single dosing and even stronger efficacy vs. other modalities, preliminary exciting clinical data is available;
EPI-003 (HBV) holds high expectations of functional cure with preliminary promising clinical data as well; EPI-004 (Obesity) with novel mechanism to address weight rebound and muscle loss, in NHP PoC. Technology focuses on empowering collaborators to develop allogeneic cell therapy using our epigenetic modulation technology, and in-vivo targeting therapies using our in-vivo LNP delivery, e.g. T cell targeting, hematopoietic stem cell targeting.
We are also open to research collaborations who intend to develop their own targets with our novel technology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}